Aclaris Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Board elections show who will lead company decisions; 80.55% participation shows strong investor engagement.
Quarterly earnings reports let investors track company progress and financial health throughout the year.
Earnings announcements reveal company revenue, costs, and profitability to help investors assess performance.
Successful drug trial results boost investor confidence that company's medicines work and may reach patients.
Stock sales raise cash for operations but dilute existing shareholders' ownership percentage.
Stock sales provide operating funds but reduce the ownership stake of current shareholders.
Annual reports show full-year profits, losses, and financial position to help long-term investment decisions.
Stocky reads Aclaris Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Aclaris Therapeutics, Inc.'s most recent tracked filing was a 8-K on 4 Jun 2026: Stockholders elect two directors through 2029 annual meeting.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.